Press Releases

Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs

By June 26, 2018 No Comments

DURHAM, North Carolina, USA, June 26 2018 –Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was led by ArrowMark Partners and was joined by new investors Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax AgTech, OCV Partners, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, and entities affiliated with Leerink Partners. Existing investors venBio, F-Prime, RA Capital Management, Amgen Ventures, Osage University Partners, DUMAC, and the Longevity Fund also participated in the financing.

View Press Release

5 Laboratory Drive
Research Triangle Park, NC 27709
Driving Directions

919.314.5512
info@elolife.ag

©2018 Elo Life Systems
Elo Life Systems is a wholly owned subsidiary of Precision BioSciences.